Anuh Pharma growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
+16.7%
+1.3%
−3.5%
−13.3%
−56.6%
+10.0%
+8.0%
−108.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ANUHPHR₹77.05

Anuh Pharma Limited

· Pharma & Health
₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹772 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+16.7—
EBITDA Growth—+1.3—
EBIT Growth—-3.5—
Net Income Growth—-13.3—
EPS Growth—-56.6—
Total Assets Growth—+10.0—
Total Equity Growth—+8.0—
Cash from Operations Growth—-108.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.